Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03288103 · ClinicalTrials.gov registry record · Phase 1
Growth Hormone Treatment in Patients With Aggrecan (ACAN) Deficiency
A Phase 1 study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT03288103 is a Phase 1 study that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 22 participants.
The verdict
NCT03288103, a Phase 1 study, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is an open-label, single-arm prospective pilot study to study the effects of a single dose regimen of daily growth hormone medication (Norditropin) on pre-pubertal children with Aggrecan deficiency. The growth response will be tracked over a 12 month period. A protocol extension has been approved to continue subjects on treatment for an additional 2 years.
Interventions
- DRUG Norditropin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2018-02-01 |
| Est. Completion | 2023-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03288103
The ClinicalTrials.gov registry entry for NCT03288103 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Norditropin is the first listed.
NCT03288103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03288103 about?
NCT03288103 is a clinical study titled "Growth Hormone Treatment in Patients With Aggrecan (ACAN) Deficiency". This is an open-label, single-arm prospective pilot study to study the effects of a single dose regimen of daily growth hormone medication (Norditropin) on pre-pubertal children with Aggrecan deficiency. The growth response will be tracked over a 12 month period. A protocol extension has been approv...
What is the current status of trial NCT03288103?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2018-02-01. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT03288103?
The interventions under investigation include: Norditropin (DRUG).
Who is sponsoring clinical trial NCT03288103?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.